Genfit S.A. ADR (GNFT)

$3.81 -0.03 (-0.78%)
Market Cap 180.49M
Revenue (ttm) 76.76M
Net Income (ttm) 1.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 2.12%
Debt to Equity Ratio 0.90
Volume 14,976
Avg Vol 7,836
Day's Range N/A - N/A
Shares Out 50.00M
Stochastic %K 46%
Beta 1.15
Analysts Strong Sell
Price Target $8.00

Company Profile

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 3 20 16 40 00
Fax: 33 2 20 16 40 01
Address:
Parc Eurasanté, 885, avenue Eugène Avinée, Loos, France
DonCorleone77
DonCorleone77 May. 20 at 8:28 PM
$GNFT $IPSEY Genfit to receive EUR 26.5M Iqirvo milestone payment from Ipsen agreement Genfit (GNFT) announced that Ipsen's Iqirvo has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis. This step unlocks a new milestone payment of EUR 26.5M under its licensing and collaboration agreement with Ipsen (IPSEY), due upon pricing and reimbursement of Iqirvo in three European markets.
0 · Reply
Armonica423
Armonica423 May. 10 at 6:20 PM
$GNFT Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
halted_stocks
halted_stocks May. 7 at 7:36 PM
$GNFT GNFT halted @ 4,11 - 15:34:43 - LUDP Volatility Trading Pause Price: 4,11 | Change: -0,51 (-11,04%) HOD: 4,58 | LOD: 4,11 | MC: 204,63M Volume: 50,47K | SMA50: 3,59 | SMA200: 4,21 Shares Outstanding: 49,79M
0 · Reply
Stocks4thought
Stocks4thought Apr. 10 at 2:25 PM
$GNFT ???
0 · Reply
Kangers_the_Lab
Kangers_the_Lab Apr. 10 at 12:34 PM
Kangers morning movers: $WHLR $KTTA $ELAB $GNFT
0 · Reply
topstockalerts
topstockalerts Apr. 10 at 11:25 AM
Pre Market Top Gainers PT2 $HYFM $HLP $GNFT $ATXS $GDTC
0 · Reply
NigelAM
NigelAM Apr. 9 at 7:54 PM
$GNFT bear trap
0 · Reply
justiceforb_85
justiceforb_85 Mar. 20 at 9:19 PM
$GNFT $XBI great news on financing. https://ir.genfit.com/news-releases/news-release-details/genfit-announces-completion-non-dilutive-royalty-financing
0 · Reply
Whiskey1679
Whiskey1679 Mar. 7 at 1:49 PM
$ICON Volume way up. Other top stocks volume of the day: $ZSPC $REE $GNFT $CTMX
0 · Reply
BLD33
BLD33 Feb. 5 at 7:23 PM
$GNFT watch the powerful biotech!!!! We can see $10 in 2025
0 · Reply
Latest News on GNFT
GENFIT: June 17, 2025 Combined Shareholders Meeting Results

Jun 17, 2025, 2:30 PM EDT - 9 days ago

GENFIT: June 17, 2025 Combined Shareholders Meeting Results

GENFIT Reports First Quarter 2025 Financial Information

May 22, 2025, 4:10 PM EDT - 5 weeks ago

GENFIT Reports First Quarter 2025 Financial Information

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy

May 20, 2025, 4:10 PM EDT - 5 weeks ago

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

May 14, 2025, 4:10 PM EDT - 6 weeks ago

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

May 7, 2025, 4:10 PM EDT - 7 weeks ago

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

GENFIT to Present Latest ACLF Research at EASL Congress 2025

May 5, 2025, 1:30 AM EDT - 7 weeks ago

GENFIT to Present Latest ACLF Research at EASL Congress 2025

GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F

Apr 29, 2025, 3:10 PM EDT - 2 months ago

GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

Apr 28, 2025, 4:10 PM EDT - 2 months ago

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

Apr 24, 2025, 4:10 PM EDT - 2 months ago

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

Apr 10, 2025, 6:56 AM EDT - 2 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

CAMP EWTX

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

Mar 20, 2025, 5:10 PM EDT - 3 months ago

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

Mar 10, 2025, 5:10 PM EDT - 3 months ago

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

GENFIT Announces Revenues and Cash Position as of December 31, 2024

Feb 27, 2025, 4:10 PM EST - 4 months ago

GENFIT Announces Revenues and Cash Position as of December 31, 2024

GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting

Feb 21, 2025, 2:30 AM EST - 4 months ago

GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting

GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders

Feb 14, 2025, 4:10 PM EST - 4 months ago

GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

Feb 6, 2025, 4:10 PM EST - 5 months ago

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

Jan 30, 2025, 2:40 AM EST - 5 months ago

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

GENFIT Announces 2025 Financial Calendar

Jan 29, 2025, 4:10 PM EST - 5 months ago

GENFIT Announces 2025 Financial Calendar

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Jan 13, 2025, 4:10 PM EST - 5 months ago

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

Nov 13, 2024, 4:10 PM EST - 8 months ago

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

GENFIT Reports Third Quarter 2024 Financial Information

Nov 7, 2024, 4:10 PM EST - 8 months ago

GENFIT Reports Third Quarter 2024 Financial Information

Top 4 Health Care Stocks That May Keep You Up At Night

Sep 24, 2024, 8:51 AM EDT - 9 months ago

Top 4 Health Care Stocks That May Keep You Up At Night

BFRG DOCS GILD

GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

Sep 23, 2024, 1:30 AM EDT - 9 months ago

GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis

Jul 26, 2024, 7:45 AM EDT - 1 year ago

GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

Jun 17, 2024, 4:10 PM EDT - 1 year ago

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis

Jun 10, 2024, 5:22 PM EDT - 1 year ago

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis

US FDA approves Genfit and Ipsen's liver disease drug

Jun 10, 2024, 5:08 PM EDT - 1 year ago

US FDA approves Genfit and Ipsen's liver disease drug

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

May 29, 2024, 4:10 PM EDT - 1 year ago

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

Genfit: Under The Radar Biotech With Upcoming Catalysts

May 29, 2024, 1:52 PM EDT - 1 year ago

Genfit: Under The Radar Biotech With Upcoming Catalysts

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

May 22, 2024, 12:05 PM EDT - 1 year ago

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

GENFIT Reports First Quarter 2024 Financial Information

May 14, 2024, 4:10 PM EDT - 1 year ago

GENFIT Reports First Quarter 2024 Financial Information

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

Apr 25, 2024, 4:10 PM EDT - 1 year ago

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

Apr 15, 2024, 4:10 PM EDT - 1 year ago

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

Apr 5, 2024, 2:00 PM EDT - 1 year ago

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

Apr 4, 2024, 4:10 PM EDT - 1 year ago

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

GENFIT Announces Revenues and Cash Position as of December 31, 2023

Feb 29, 2024, 4:10 PM EST - 1 year ago

GENFIT Announces Revenues and Cash Position as of December 31, 2023

GENFIT Announces 2024 Financial Calendar

Jan 15, 2024, 4:10 PM EST - 1 year ago

GENFIT Announces 2024 Financial Calendar

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

Dec 8, 2023, 1:55 AM EST - 1 year ago

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

Dec 6, 2023, 11:30 AM EST - 1 year ago

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

Genfit: Large PBC Market, Liquidity To Await Approval

Nov 27, 2023, 7:30 AM EST - 1 year ago

Genfit: Large PBC Market, Liquidity To Await Approval

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Nov 16, 2023, 4:10 PM EST - 1 year ago

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

Nov 13, 2023, 4:30 PM EST - 1 year ago

GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

GENFIT Reports Third Quarter 2023 Financial Information

Nov 9, 2023, 4:10 PM EST - 1 year ago

GENFIT Reports Third Quarter 2023 Financial Information

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

Nov 2, 2023, 5:10 PM EDT - 1 year ago

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

Sep 26, 2023, 4:10 PM EDT - 1 year ago

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

GENFIT to Participate in Upcoming Investor Conferences

Sep 5, 2023, 4:10 PM EDT - 1 year ago

GENFIT to Participate in Upcoming Investor Conferences

GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

Aug 10, 2023, 4:10 PM EDT - 2 years ago

GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

These strategists say investors need quality, so sell Tesla and AMD, and buy these stocks instead.

Jun 30, 2023, 6:56 AM EDT - 2 years ago

These strategists say investors need quality, so sell Tesla and AMD, and buy these stocks instead.

AAPL NKE

U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease

Jun 30, 2023, 6:44 AM EDT - 2 years ago

U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Jun 30, 2023, 1:00 AM EDT - 2 years ago

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

DonCorleone77
DonCorleone77 May. 20 at 8:28 PM
$GNFT $IPSEY Genfit to receive EUR 26.5M Iqirvo milestone payment from Ipsen agreement Genfit (GNFT) announced that Ipsen's Iqirvo has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis. This step unlocks a new milestone payment of EUR 26.5M under its licensing and collaboration agreement with Ipsen (IPSEY), due upon pricing and reimbursement of Iqirvo in three European markets.
0 · Reply
Armonica423
Armonica423 May. 10 at 6:20 PM
$GNFT Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
halted_stocks
halted_stocks May. 7 at 7:36 PM
$GNFT GNFT halted @ 4,11 - 15:34:43 - LUDP Volatility Trading Pause Price: 4,11 | Change: -0,51 (-11,04%) HOD: 4,58 | LOD: 4,11 | MC: 204,63M Volume: 50,47K | SMA50: 3,59 | SMA200: 4,21 Shares Outstanding: 49,79M
0 · Reply
Stocks4thought
Stocks4thought Apr. 10 at 2:25 PM
$GNFT ???
0 · Reply
Kangers_the_Lab
Kangers_the_Lab Apr. 10 at 12:34 PM
Kangers morning movers: $WHLR $KTTA $ELAB $GNFT
0 · Reply
topstockalerts
topstockalerts Apr. 10 at 11:25 AM
Pre Market Top Gainers PT2 $HYFM $HLP $GNFT $ATXS $GDTC
0 · Reply
NigelAM
NigelAM Apr. 9 at 7:54 PM
$GNFT bear trap
0 · Reply
justiceforb_85
justiceforb_85 Mar. 20 at 9:19 PM
$GNFT $XBI great news on financing. https://ir.genfit.com/news-releases/news-release-details/genfit-announces-completion-non-dilutive-royalty-financing
0 · Reply
Whiskey1679
Whiskey1679 Mar. 7 at 1:49 PM
$ICON Volume way up. Other top stocks volume of the day: $ZSPC $REE $GNFT $CTMX
0 · Reply
BLD33
BLD33 Feb. 5 at 7:23 PM
$GNFT watch the powerful biotech!!!! We can see $10 in 2025
0 · Reply
Stocks4thought
Stocks4thought Feb. 5 at 4:12 PM
$GNFT hot
0 · Reply
BLD33
BLD33 Dec. 28 at 7:23 PM
$GNFT 2025 will be Fabulous. Ipsen sold already in Germany, coming other countries. FDA approval coming 24 millions It trade at 24 when no drug approved, we should run back to this level. Other pipelines in 2025
0 · Reply
justiceforb_85
justiceforb_85 Dec. 1 at 4:37 AM
$GNFT appears next milestone will be for GNS561 in cholangiocarcinoma. Hoping for good news.
0 · Reply
yourwellwisher
yourwellwisher Nov. 6 at 2:10 AM
$GNFT making the move after hours. Soon double digits as planned
0 · Reply
justiceforb_85
justiceforb_85 Oct. 24 at 11:24 PM
$GNFT awaiting read-outs for cholangiocarcinoma and acute-on-chronic liver failure treatments.
0 · Reply
cacaelma
cacaelma Oct. 23 at 11:57 AM
$GNFT from Ipsen's YTD 2024 sales update related to the launch of Iqirvo licensed form $GNFT
0 · Reply
yourwellwisher
yourwellwisher Oct. 21 at 11:15 AM
$GNFT coming together. Wait for the news as it pops into double digits.
0 · Reply
yourwellwisher
yourwellwisher Oct. 18 at 6:31 PM
Watch out for $GNFT in coming weeks
0 · Reply
justiceforb_85
justiceforb_85 Oct. 17 at 9:50 PM
$GNFT $XBI very under the radar. Data for GNS561 in cholangiocarcinoma out later this year.
0 · Reply